ROSEN, A LEADING NATIONAL FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...
The Harvard Crimson1d
Biopharma Giant GSK to Expand Research and Development Footprint in Cambridge
International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...
Le Lézard3d
PENMENVY, GSK's 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 ...
Electric car-charging firm boss admits company broke law a week after receiving £55m from taxpayers
THE boss of an electric car-charging firm that last week received £55million from taxpayers has admitted it broke the law by ...
Insider Monkey15d
Why GSK plc (GSK) Went Up on Wednesday
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...
Seeking Alpha15d
GSK outlines 2025 growth driven by specialty medicines and new product launches
The company plans five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. Specialty medicines accounted for more than 80% of GSK's growth in ...
Seeking Alpha15d
GSK raises long-term guidance, announces buybacks
GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025.
Insider Monkey15d
Why GSK Stock Is Surging Today
GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...
The Irish News15d
GSK lifts long-term sales targets on new drug pipeline
and GSK has to prove its drug development pipeline is packed with new blockbuster treatments. “An increased dividend and the launch of a first major share buyback in more than a decade suggest ...
Yahoo Finance15d
GSK lifts long-term sales targets on new drug pipeline
GSK said it expects core operating profits to rise by between 6% and 8% this year, with turnover said to lift by between 3% and 5%. It said it expects further growth to be boosted by its strong ...
This is Local London15d
GSK lifts long-term sales targets on new drug pipeline
Pharmaceutical giant GlaxoSmithKline (GSK ... It said it expects further growth to be boosted by its strong pipeline of new drugs, with 71 specialty medicines and vaccines now in clinical development.